新型冠状病毒原始株与流行株IgG抗体组合在识别Omicron BA.5流行株感染中的应用
本研究纳入Omicron BF.7/BA.5自然感染人群、疫苗免后健康人群及Omicron BF.7/BA.5免疫突破感染病例,用间接ELISA法检测血清原始株Spike IgG(WT-S-IgG)与Omicron BA.5 Spike IgG(BA.5-S-IgG)抗体滴度并比较。免疫突破病例两种抗体滴度均高于自然感染人群和健康人群(均P<0.05);两种抗体及比值识别Omicron BA.5流行株感染具有较高应用价值。
要点
- 免疫突破病例WT-S-IgG和BA.5-S-IgG滴度均高于自然感染人群和疫苗免后健康人群(均P<0.05)。
- WT-S-IgG与BA.5-S-IgG识别Omicron BA.5流行株感染的ROC曲线下面积分别为0.947和0.961。
- BA.5-S-IgG与WT-S-IgG滴度比值识别流行株感染的AUC为0.873,比值0.855时灵敏度80%、特异度90%。
核心结论
- BA.5-S-IgG和WT-S-IgG两种血清抗体滴度及其比值在识别Omicron BA.5流行株感染具有较高应用价值。
研究设计与样本
- 研究纳入新冠高强度流行后的Omicron BF.7/BA.5自然感染人群、疫苗免后健康人群和免疫突破感染Omicron BF.7/BA.5病例为研究对象。
- 应用间接ELISA法检测血清WT-S-IgG和BA.5-S-IgG抗体滴度并比较不同人群抗体水平。
- 应用ROC曲线探索两种抗体滴度及两种抗体滴度比值在识别流行Omicron BA.5株感染中的应用价值。
主要发现
- 免疫突破感染Omicron BF.7/BA.5病例的WT-S-IgG和BA.5-S-IgG两种抗体滴度水平明显高于Omicron BF.7/BA.5自然感染人群和疫苗免后健康人群(均P<0.05)。
- WT-S-IgG和BA.5-S-IgG抗体识别Omicron BA.5流行株感染ROC曲线下面积分别为0.947和0.961。
- BA.5-S-IgG与WT-S-IgG抗体滴度比值识别流行株感染AUC为0.873,当该比值为0.855时,灵敏度及特异度分别为80%和90%。
- 按感染后时长分类,BA.5-S-IgG与WT-S-IgG抗体滴度比值识别≤30 d和>30 d流行株感染的ROC曲线下面积分别为0.887和0.863,灵敏度和特异度均达到80%以上。
关键数值与推荐
- WT-S-IgG识别Omicron BA.5流行株感染的ROC曲线下面积为0.947。
- BA.5-S-IgG识别Omicron BA.5流行株感染的ROC曲线下面积为0.961。
- BA.5-S-IgG与WT-S-IgG抗体滴度比值识别流行株感染的AUC为0.873。
- BA.5-S-IgG与WT-S-IgG抗体滴度比值为0.855时,灵敏度为80.00%,特异度为90.00%。
- BA.5-S-IgG与WT-S-IgG抗体滴度比值识别≤30 d流行株感染的AUC为0.887,识别>30 d流行株感染的AUC为0.863,灵敏度和特异度均达到80%以上。
临床怎么用
- 原文结论认为BA.5-S-IgG和WT-S-IgG两种血清抗体滴度及其比值在识别Omicron BA.5流行株感染具有较高应用价值,可为病原体诊断提供技术支撑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the application of COVID-19-specific IgG antibody in identifying epidemic Omicron BA.5 strain infection. Method: Omicron BF.7/BA.5 naturally infected population, healthy population vaccinated with the COVID-19 vaccine, and Omicron BF.7/BA.5 breakthrough cases were enrolled into this study. The serum WT-S-IgG and BA.5-S-IgG were detected by indirect ELISA, and the serum-specific IgG antibody levels of different populations were compared. The application value of the two antibody titers and the ratio of the two antibodies in identifying Omicron BA.5 epidemic strain infection were explored by the ROC curve, aiming to provide technical support for pathogen diagnosis. Results: The antibody titers of WT-S-IgG and BA.5-S-IgG in the breakthrough cases were higher than those in the naturally infected population and the healthy population (P<0.05). The area under the curve (AUC) of WT-S-IgG and BA.5-S-IgG in identifying epidemic Omicron BA.5 strain infection was 0.947 and 0.961, respectively. The AUC of BA.5-S-IgG and WT-S-IgG antibody titer ratio was 0.873. When the antibody titer ratio was 0.855, the sensitivity and specificity were 80.00% and 90.00%, respectively. According to the interval since the last infection, the AUC of the ratio of BA.5-S-IgG to WT-S-IgG antibody titer to identify the infection of epidemic strains less than 30 days and more than 30 days was 0.887 and 0.863, respectively, and the sensitivity and specificity were both above 80%. Conclusion: Both BA.5-S-IgG and WT-S-IgG, as well as the combination of these two antibodies, are of high value in the identification of epidemic strains. 目的: 探讨新型冠状病毒特异性IgG抗体组合在识别Omicron BA.5流行株感染的应用。 方法: 选择新冠高强度流行后的Omicron BF.7/BA.5自然感染人群、疫苗免后健康人群和免疫突破感染Omicron BF.7/BA.5病例为研究对象,应用间接ELISA法检测血清原始株和流行株特异性IgG抗体滴度,并比较不同人群血清特异性IgG抗体水平。应用ROC曲线探索新型冠状病毒原始型Spike IgG抗体(WT-S-IgG)和新型冠状病毒Spike(Omicron BA.5)IgG抗体(BA.5-S-IgG)两种抗体滴度以及两种抗体滴度比值在识别流行Omicron BA.5株感染中的应用价值,为病原体诊断提供技术支撑。 结果: 免疫突破感染Omicron BF.7/BA.5病例的WT-S-IgG和BA.5-S-IgG两种抗体滴度水平明显高于Omicron BF.7/BA.5自然感染人群和疫苗免后健康人群(均P<0.05)。WT-S-IgG和BA.5-S-IgG抗体识别Omicron BA.5流行株感染ROC曲线下面积分别为0.947和0.961。BA.5-S-IgG与WT-S-IgG抗体滴度比值识别流行株感染AUC为0.873,当该比值为0.855时,灵敏度及特异度分别为80%和90%。按照感染者的感染后时长分类,BA.5-S-IgG与WT-S-IgG抗体滴度的比值识别≤30 d和>30 d流行株感染的ROC曲线下面积分别为0.887和0.863,灵敏度和特异度均达到80%以上。 结论: BA.5-S-IgG和WT-S-IgG两种血清抗体滴度及其比值在识别Omicron BA.5流行株感染具有较高应用价值。.
引用
- Chu JJ, Tian H, Li CC, et al. [Application of IgG antibody combination of wild strain and epidemic strain of COVID-19 in identifying epidemic Omicron BA.5 strain infection]. Zhonghua Yu Fang Yi Xue Za Zhi. 2024. PMID: 39290016. doi:10.3760/cma.j.cn112150-20240101-00002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。